The DOI matches its Crossref record.
Antiretroviral activity of 5-azacytidine during treatment of a HTLV-1 positive myelodysplastic syndrome with autoimmune manifestations
Open accessAbstract
Myelodysplastic syndromes (MDS) are often accompanied by autoimmune phenomena. The underlying mechanisms for these associations remain uncertain, although T cell activation seems to be important. Human T-lymphotropic virus (HTLV-1) has been detected in patients with myelodysplastic syndromes, mostly in regions of the world which are endemic for the virus, and where association of HTLV-1 with rheumatological manifestation is not rare. We present here the case of a 58 year old man who presented with cytopenias, leukocytoclastic vasculitis of the skin and glomerulopathy, and was diagnosed as MDS (refractory anemia with excess blasts - RAEB 1). The patient also tested positive for HTLV-1 by PCR. After 8 monthly cycles of 5-azacytidine he achieved a complete hematologic remission. Following treatment, a second PCR for HTLV-1 was carried out and found to be negative. This is the first report in the literature of a HTLV-1-positive MDS with severe autoimmune manifestations, which was treated with the hypomethylating factor 5-azacitidine, achieving cytogenetic remission with concomitant resolution of the autoimmune manifestations, as well as HTLV-1-PCR negativity. HTLV-1-PCR negativity may be due to either immune mediated clearance of the virus, or a potential antiretroviral effect of 5-azacytidine. 5-azacytidine is known for its antiretroviral effects, although there is no proof of its activity against HTLV-1 infection in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Nooraei, S., Bahrulolum, H., Hoseini, Z. S., Katalani, C., Hajizade, A., Easton, A. J., & Ahmadian, G. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00806-7 · Cited by 869
Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades?
Vallet-Regí, M., Schüth, F., Lozano, D., Colilla, M., & Manzano, M. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00659b · Cited by 507
Rethinking wastewater risks and monitoring in light of the COVID-19 pandemic
Bogler, A., Packman, A., Furman, A., Gross, A., Kushmaro, A., Ronen, A., Dagot, C., Hill, C., Vaizel-Ohayon, D., Morgenroth, E., et al. (2020) · Nature Sustainability · doi:10.1038/s41893-020-00605-2 · Cited by 312
Biologically active polysaccharide from edible mushrooms: A review
Maity, P., Sen, I. K., Chakraborty, I., Mondal, S., Bar, H., Bhanja, S. K., Mandal, S., & Maity, G. N. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.01.081 · Cited by 253
Latsuzbaia, A., Tapp, J., Nguyen, T., Fischer, M., Arbyn, M., Weyers, S., & Mossong, J. (2016) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2016.04.011 · Cited by 27
Metadata
- Authors
- Diamantopoulos, P. T., Michael, M., Benopoulou, O., Bazanis, E., Tzeletas, G., Meletis, J., Vayopoulos, G., & Viniou, N.-A.
- Venue
- Virology Journal
- Published
- 2012-01-03
- Volume
- 9
- Issue
- 1
- Pages
- 1-1
- ISSN
- 1743-422X (ISSN-L)
- OpenAlex
- W2133492691
- Cited by
- 243
- References
- 0
- FWCI
- 6.53
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antiretroviral activity of 5-azacytidine during treatment of a HTLV-1 positive myelodysplastic syndrome with autoimmune manifestations. https://app.cochat.ai/papers/10.1186/1743-422x-9-1
- The paper
- Diamantopoulos, P. T., Michael, M., Benopoulou, O., Bazanis, E., Tzeletas, G., Meletis, J., Vayopoulos, G., & Viniou, N.-A. (2012). Antiretroviral activity of 5-azacytidine during treatment of a HTLV-1 positive myelodysplastic syndrome with autoimmune manifestations. Virology Journal. https://doi.org/10.1186/1743-422x-9-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.